loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Sakar Healthcare has received 14 new oncology product approvals across the EU

ICICIdirect Research 02 Sep 2026 DISCLAIMER

News: Sakar Healthcare has received 14 new oncology product approvals across the EU, UK and Canada through seven business partners, strengthening its presence in regulated markets. Accord, the company’s frontrunner partner, received five additional product site variations approved by the EMA, taking the number of approved technology transfers initiated with the partner to six out of eight. Two other partners—located in the UK and Germany—received approvals for three products from the MHRA and EMA, respectively, while six of Sakar’s licensed-out products received marketing authorisations, including four in the EU and one each in the UK and Canada. The approvals cover treatments for multiple cancer indications, including breast, lung, prostate, stomach, head and neck, colon and rectum, ovary, liver, kidney, blood, bone marrow and lymphoma. 

View: This development is in line with management's guidance and our expectations of receiving increasing marketing authorisation in this and the following year (taking the count to 30 vs 16 in Q1FY27). The progress in regulated markets would strengthen its position and support top-line growth through its business partnerships and technology-transfer models. We continue to monitor the progress of Sakar receiving further marketing authorisations.

Impact: Positive

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere